Discover how Chroma is expanding our impact.

Boston, September 16, 2024 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, presented new preclinical data demonstrating the potency of its optimized HBV-targeted epigenetic editor, CRMA-1001, in an oral presentation at the 2024 International HBV Meeting, held September 11-15 in Chicago. These data, along with data from an earlier generation HBV-targeted epigenetic editor, underscore the potential for CRMA-1001 to improve the rate of functional cures in patients with HBV. CRMA-1001 is designed to silence both covalently closed circular DNA (cccDNA) and integrated DNA at the level of transcription without cutting or nicking the DNA, permanently inactivating…

Boston, MA, September 3, 2024 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, presented new preclinical data demonstrating the potency, durability, and specificity of its PCSK9-targeted epigenetic editor in an oral presentation at the 2024 European Society of Cardiology Congress, held August 30-September 2 in London. The data showcase the potential best-in-class potency achievable in NHPs with Chroma’s optimized epigenetic editors. They also indicate the company’s epigenetic editing platform can effectively silence expression of PCSK9 in the liver, inducing durable reductions in low-density lipoprotein-cholesterol (LDL-C) levels without cutting or nicking the DNA. The PCSK9 gene actively promotes the degradation of…

Boston, MA, July 18, 2024 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, today announced the appointment of Melissa J. Moore, Ph.D., to its Board of Directors. “Melissa brings decades of experience directing RNA research and drug development at leading pharma companies and in academia,” said Catherine Stehman-Breen, M.D., CEO of Chroma. “Her deep knowledge will benefit us as we advance our platform of highly potent and durable epigenetic editors to patients, enabling a new class of genomic medicines.” Currently serving as a Board Director and Scientific Advisory Board member for multiple biotechnology companies, Dr. Moore…

Boston, MA, June 27, 2024 – Chroma Medicine, Inc. (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, today announced it has entered into an exclusive license agreement with the Whitehead Institute to access intellectual property and technology developed in the lab of Chroma co-founder Jonathan Weissman, Ph.D.  The novel technology called CHARM (coupled histone tail for autoinhibition release of methyltransferase) uses a compact epigenetic editing effector domain to recruit and activate endogenous DNA methyltransferases to durably silence target genes. CHARM can utilize a self-silencing mechanism to limit its duration of expression and has been shown by Dr. Weissman’s lab to…